Nullscript (CAS 300816-11-9)
QUICK LINKS
Nullscript serves as a negative control in studies involving the histone deacetylase (HDAC) inhibitor Scriptaid. This compound is structurally similar to Scriptaid but lacks the functional group necessary for HDAC inhibition, making it valuable for discerning specific drug effects from off-target effects in research. Its role is in experiments designed to validate the specificity and efficacy of HDAC inhibition by Scriptaid in various biological processes such as gene expression, epigenetic regulation, and chromatin remodeling. By using Nullscript, researchers can also better understand the non-HDAC related activities of Scriptaid, providing a clearer insight into the compound′s mechanism of action. This control compound is essential for ensuring the reliability and accuracy of experimental data in epigenetics research, where HDAC inhibitors are studied for their potential to modulate chromatin structure and function.
Nullscript (CAS 300816-11-9) References
- High-throughput drug screening of the DPC4 tumor-suppressor pathway in human pancreatic cancer cells. | Sohn, TA., et al. 2001. Ann Surg. 233: 696-703. PMID: 11323508
- Cardiac hypertrophy and histone deacetylase-dependent transcriptional repression mediated by the atypical homeodomain protein Hop. | Kook, H., et al. 2003. J Clin Invest. 112: 863-71. PMID: 12975471
- Histone deacetylase inhibitors and transforming growth factor-beta induce 15-hydroxyprostaglandin dehydrogenase expression in human lung adenocarcinoma cells. | Tong, M., et al. 2006. Biochem Pharmacol. 72: 701-9. PMID: 16844092
- 15-hydroxyprostaglandin dehydrogenase (15-PGDH) and lung cancer. | Tai, HH., et al. 2007. Prostaglandins Other Lipid Mediat. 83: 203-8. PMID: 17481556
- Preclinical studies of chemotherapy using histone deacetylase inhibitors in endometrial cancer. | Takai, N. and Narahara, H. 2010. Obstet Gynecol Int. 2010: 923824. PMID: 20169171
- Histone deacetylase inhibitors de-repress tyrosine hydroxylase expression in the olfactory bulb and rostral migratory stream. | Akiba, Y., et al. 2010. Biochem Biophys Res Commun. 393: 673-7. PMID: 20170631
- High mobility group box 1 release from hepatocytes during ischemia and reperfusion injury is mediated by decreased histone deacetylase activity. | Evankovich, J., et al. 2010. J Biol Chem. 285: 39888-97. PMID: 20937823
- Regulation of kidney development by histone deacetylases. | Rosenberg, SL., et al. 2011. Pediatr Nephrol. 26: 1445-52. PMID: 21336812
- Hydroxamic acid-based histone deacetylase (HDAC) inhibitors can mediate neuroprotection independent of HDAC inhibition. | Sleiman, SF., et al. 2014. J Neurosci. 34: 14328-37. PMID: 25339746
- Hydroxamate-based histone deacetylase inhibitors can protect neurons from oxidative stress via a histone deacetylase-independent catalase-like mechanism. | Olson, DE., et al. 2015. Chem Biol. 22: 439-445. PMID: 25892200
- Nullscript inhibits Cryptosporidium and Toxoplasma growth. | Murakoshi, F., et al. 2020. Int J Parasitol Drugs Drug Resist. 14: 159-166. PMID: 33120250
- Defining a pharmacological inhibitor fingerprint for oxytosis/ferroptosis. | Soriano-Castell, D., et al. 2021. Free Radic Biol Med. 171: 219-231. PMID: 34010663
- Intracellular fluorescence competition assay for inhibitor engagement of histone deacetylase. | Padilla-Coley, S., et al. 2021. Bioorg Med Chem Lett. 47: 128207. PMID: 34146703
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Nullscript, 1 mg | sc-222084 | 1 mg | $77.00 | |||
Nullscript, 5 mg | sc-222084A | 5 mg | $306.00 |